How many approved drugs

Skip to main content Try our corporate solution for free! Single Accounts Corporate Solutions Universities. Premium statistics. Read more. The number of new medicinal products entering the pharmaceutical market each year varies heavily: just over 20 novel drugs were introduced in , while about 60 new products were approved in There were 53 approvals for novel drugs in Biopharma medicines in development Many new drugs are being developed in , and that is especially true for the U.

As of April , over 1, new medicines were in development for cancer and cancer-related conditions alone in the United States. Hundreds of novel medicines were also in development for rare diseases, neurological disorders, and skin diseases. Cost of drug development: then vs. Over the past few decades, such expenses have increased, reaching roughly 2.

In , almost 15 percent of the revenue generated by the U. Between and , the percentage was closer to 21 percent. You need a Single Account for unlimited access. Full access to 1m statistics Incl. Single Account. View for free. But the paper also takes a look at something which receives far less attention in drug development: Unique companies with approved NMEs.

In the s through , fewer than 20 companies had drugs approved for sale in the US. As early as , fewer than 60 companies did. Though more than 90 companies now have approved NMEs, there has been a decrease in the number of companies with approved NMEs in recent years due to a large number of mergers, acquisitions, repositioning and market exits, Kinch found.

However, one company is a clear leader in the number of approved NMEs now controlled. Thank you for visiting nature. You are using a browser version with limited support for CSS.

To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Update 18 January : Information on the financial performance of the new drugs approved and the characteristics of the reviews by the FDA has been added to the article, with an additional column in Table 1 and Figure 4.

For example, CDER classifies biological products submitted in an application under section a of the Public Health Service Act as NMEs for purposes of FDA review, regardless of whether the Agency previously has approved a related active moiety in a different product. To see the FDA-approved conditions of use [e. To treat overactive bladder Drug Trials Snapshot. To treat ebola Drug Trials Snapshot. To treat actinic Keratosis of the face or scalp Drug Trials Snapshot.

To treat patients with hereditary angioedema Drug Trials Snapshot. Gallium 68 PSMA To treat high-risk refractory or relapsed neuroblastoma Drug Trials Snapshot.

To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early age Drug Trials Snapshot.